0.00Open10.00Pre Close0 Volume6 Open Interest15.00Strike Price0.00Turnover0.00%IV10.64%PremiumJan 17, 2025Expiry Date7.60Intrinsic Value100Multiplier24DDays to Expiry2.41Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.12Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet